What did MPs oppose about NHS drug pricing?

MPs oppose power to override NICE drug cost decisions

Dozens of MPs have come out against a move linked to Health Secretary Wes Streeting’s plan to change how the NHS decides what it pays for medicines. The central objection is that Streeting would gain new authority to override decisions made by NICE, the body that evaluates whether treatments offer value for money.

The controversy described in the report frames the policy change as both a “power grab” and potentially unlawful. MPs opposing the plan argue it could undermine the role of NICE and shift influence toward commercial interests—particularly as the plan is said to benefit big pharmaceutical companies.

Why this matters for public health is that NICE assessments can directly affect whether and how quickly medicines reach patients in the NHS. When coverage decisions are tied to value-for-money judgments, changes to the decision-making structure can alter:

• Access timing: Whether patients receive newer therapies sooner or later depends on how overrides are implemented.
• Spending priorities: If decisions are overridden away from NICE’s cost-effectiveness framework, it could change the balance of NHS budgets across services and drugs.
• Governance and accountability: MPs raising legality concerns indicate that the institutional process for medicine appraisal may be at stake.

The report underscores that the policy shift comes amid growing concern that it could be used to steer NHS reimbursement outcomes away from NICE’s recommendations.

In short, the dispute is not about clinical effectiveness alone; it is about who gets to decide what the health system funds for drugs—NICE or ministers with expanded override powers—and how that governance change could affect patients and budgets.